Morphic Therapeutic
Morphic Therapeutic is pioneering the development of oral integrin medicines, leveraging decades of expertise to transform treatment paradigms for patients with conditions such as inflammatory bowel disease, autoimmune diseases, fibrosis, and cancer.
Company Overview
Morphic Therapeutic is pioneering the development of oral integrin medicines to transform treatment paradigms for patients. The company leverages decades of expertise in integrin biology to discover and develop therapeutically relevant small molecule integrin inhibitors and activators. Morphic Therapeutic's MInT (Morphic Integrin Technology) platform integrates integrin biology, structural analysis, therapeutic design, and translational development. The company is based in Waltham, MA.
Lead Candidate: MORF-057
Morphic Therapeutic's lead candidate, MORF-057, is a highly specific, orally-available inhibitor of α4β7 integrin. It is currently in Phase 2 clinical trials for the treatment of inflammatory bowel disease (IBD). The EMERALD clinical trials, which include the EMERALD-1 phase 2a study and the EMERALD-2 phase 2b study, are investigating the efficacy and safety of MORF-057 in patients with ulcerative colitis.
Therapeutic Pipeline
Morphic Therapeutic's pipeline extends across multiple therapeutic areas, including autoimmune diseases, fibrosis, and cancer. The company is developing small molecule inhibitors of integrin α5β1 for indications such as severe pulmonary hypertensive disease. Additionally, Morphic Therapeutic is advancing small molecule inhibitors of integrin αvβ8 for potential applications in myelofibrosis and combination immuno-oncology approaches for solid tumors. The pipeline also includes next-generation α4β7 small molecule inhibitors with enhanced attributes.
Research Collaborations
Morphic Therapeutic entered a research partnership with Janssen in 2019 to discover inhibitors targeting undisclosed integrin targets. In 2021, this collaboration was expanded to include an antibody activator of an integrin target. These partnerships aim to leverage Morphic's advanced integrin discovery platform to develop innovative therapeutic solutions.
MInT Platform
Morphic Therapeutic's MInT (Morphic Integrin Technology) platform is a key component in the company's drug discovery and development efforts. The platform combines integrin biology, structural analysis, therapeutic design, and translational development to modulate integrin activity for treating various diseases. Morphic's MInT platform applies to all members of the 24-member integrin family and includes the development of both inhibitors and activators.